Discovery Of Covalent Ligands To Novel E3 Ligases Enables Bispecific Degraders With Highly Differentiated Protein Degradation Across A Broad Range Of Targets
CANCER RESEARCH(2020)
Abstract
Introduction: Targeted protein degradation is a novel therapeutic modality that holds great promise. Current bispecific degraders have been mostly built using reversible ligands against two well characterized E3 ligases, CRBN and VHL. Features unique to each particular E3 ligase, such as its tissue expression pattern or its intrinsic catalytic efficiency could ultimately impact the in vivo bioactivity of any bifunctional drug based on it. Therefore, discovering ligands to novel E3s has the potential to enable a new class of drugs with substantially differentiated pharmacology compared to CRBN- or VHL-based degraders. Our unique covalent small molecule library and proteomics platform is an ideal tool for discovering ligands against novel E3s. Experimental plan: Utilize Vividion9s chemical proteomics platform to screen for ligands capable of covalently engaging novel E3s and driving targeted degradation when configured in bifunctional formats. Summary of Results: Initial screens identified covalent ligands capable of potently engaging numerous E3 ligases, including members of the Cullin E3s, other RING-containing ligases and HECT E3 ligases. We describe here a representative molecule from this screening effort that was advanced to engagement potencies of 50% degradation the target proteins at doses Citation Format: Kristen Baltgalvis, Shota Kikuchi, Kent Symons, Joseph Klebba, Lena Luukkonen, Yuta Naro, Colin Walsh, Joon Chang, Charles Chapman, Ali Tabatabaei, Brian Nordin, Christie Eissler, Joel Chick, Landon Whitby, Jaclyn Brannon, Gabe Simon, Matt Patricelli, Dean Stamos, Larry Burgess, Todd Kinsella. Discovery of covalent ligands to novel E3 ligases enables bispecific degraders with highly differentiated protein degradation across a broad range of targets [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6411.
MoreTranslated text
Key words
bispecific degraders,e3 ligases,protein degradation,covalent ligands
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined